Hepatic oncology (BCLC)

Featured projects

Rational to modulate the microbiome-induced endoplasmic reticulum stress as tool to avoid the immune evasion in Hepatocellular Carcinoma (RETO)

Principal investigator: María Reig Monzón.
Funder: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); Asociación Española Contra el Cáncer .

Code: PRYCO234831REIG.

Duration: 01/01/2024 - 01/01/2028
Plasticidad tumoral y la regulación de anhidrasa carbónica 9 en carcinoma hepatocelular. Base racional para modular la evasión inmunológica y mejorar la respuesta al tratamiento.

Principal investigator: María Reig Monzón.
Funder: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); Instituto de Salud Carlos III .

Code: PI22/01427.

Duration: 01/01/2023 - 01/01/2025
IMMUNE4ALL, Exploring the Feasibility of predictive and pharmacodynamics biomarkers of immunotherapy in solid tumors

Principal investigator: María Reig Monzón.
Funder: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); European Union - CIBERONC .

Code: S2300092_3.

Duration: 01/01/2023 - 31/12/2025
Epithelioid Hemangioendothelioma International Network

Principal investigator: Jordi Rimola, María Reig Monzón.
Funder: European Association for the Study of the Liver - EASL .

Code: EHIN.

Duration: 01/06/2021 - 01/06/2026

Summary:
Project Title: Epithelioid Hemangioendothelioma International Network Project reference: N/A PI: Jordi Rimola Funding Agency: EASL Funding: 50000 eur Duration: 2021-2026
A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology

Principal investigator: Jordi Rimola Gibert, Aleix Prat Aparicio.
Funder: European Commission .

Code: CE_H2020_SC1_20_1s13.

Duration: 01/10/2020 - 30/09/2024
"Improving immunotherapy in hepatocellular carcinoma via PD-1-TGFβ cotargeting"

Principal investigator: María Reig Monzón.
Funder: CIBEReHD .

Code: 20PI04.

Duration: 02/04/2020 - 01/04/2022

Summary:
Proyecto Competitivo Ciber.
Importancia del inflamasoma en la sensibilidad o resistencia a los inhibidores tirosina quinasa en pacientes con cáncer de hígado (PI18/00358) ( Importance of the inflammasome in the sensitivity or resistance to tyrosine kinase inhibitors in patients with

Principal investigator: María Reig Monzón.
Funder: Instituto de Salud Carlos III .

Duration: 01/01/2019 - 31/12/2022
Rendimiento de la RM con ácido gadoxético para el diagnóstico y estadiaje del carcinoma hepatocelular

Principal investigator: Alejandro Forner Gonzalez.
Funder: Instuto de Salud Carlos III ; Hospita Clinic de Barcelona (Sede o evento).

Code: PI18/00542.

Duration: 01/01/2019 - 31/12/2021
AECC Clínico 2018: Prospective clinical evaluation of the genetic-immuno / inflammatory profile in the treatment of hepatocellular carcinoma with sorafenib to predict tolerance and survival"

Principal investigator: Alvaro Díaz González, María Reig Monzón.
Funder: Asociación Española Contra el Cáncer (AECC). ; Asociación Española Contra el Cáncer (AECC) .

Code: CLJUN18016DIAZ.

Duration: 01/08/2018 - 31/12/2019
A phase I open label, clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).

Principal investigator: Jordi Bruix Tudo.
Funder: Adaptimmune .

Code: ADP-0033-001.

Duration: 01/01/2018 - 31/12/2033

The research of this group can be carried out thanks to the funders.

Featured projects

Rational to modulate the microbiome-induced endoplasmic reticulum stress as tool to avoid the immune evasion in Hepatocellular Carcinoma (RETO)

Plasticidad tumoral y la regulación de anhidrasa carbónica 9 en carcinoma hepatocelular. Base racional para modular la evasión inmunológica y mejorar la respuesta al tratamiento.

IMMUNE4ALL, Exploring the Feasibility of predictive and pharmacodynamics biomarkers of immunotherapy in solid tumors

Epithelioid Hemangioendothelioma International Network

A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology

"Improving immunotherapy in hepatocellular carcinoma via PD-1-TGFβ cotargeting"

Importancia del inflamasoma en la sensibilidad o resistencia a los inhibidores tirosina quinasa en pacientes con cáncer de hígado (PI18/00358) ( Importance of the inflammasome in the sensitivity or resistance to tyrosine kinase inhibitors in patients with

Rendimiento de la RM con ácido gadoxético para el diagnóstico y estadiaje del carcinoma hepatocelular

AECC Clínico 2018: Prospective clinical evaluation of the genetic-immuno / inflammatory profile in the treatment of hepatocellular carcinoma with sorafenib to predict tolerance and survival"

A phase I open label, clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).

Major founders